KBY Biotech Indexv0.0.34
Search
← Pipeline|CSL-5840

CSL-5840

Phase 3
By CSL Limited
Source: Trial-derived·Trials: 1
Modality
mAb
MOA
PCSK9i
Target
GPRC5D
Pathway
RAS/MAPK
Celiac
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
Jan 2019
Phase 3Current
NCT04425160
1,884 pts·Celiac
2019-01→TBD·Terminated
1,884 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2019
P3
Termina…
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04425160Phase 3CeliacTerminated1884DAS28
Competitors (10)
DrugCompanyPhaseTargetMOA
PexatenlimabNovartisPhase 1/2GPRC5DKIF18Ai
MRK-8368Merck & CoPhase 3ALKPCSK9i
RibotuximabMerck & CoPhase 2GPRC5DEZH2i
RibofutibatinibAstraZenecaPhase 2/3SOS1PCSK9i
AZN-4015AstraZenecaPreclinicalBCMAPCSK9i
BMY-9931Bristol-Myers SquibbPhase 1GPRC5DFXIai
NVO-7877Novo NordiskPreclinicalGPRC5DFXIai
PolazasiranAmgenPhase 2LAG-3PCSK9i
AMG-9654AmgenPhase 2GPRC5DDLL3 ADC
GIL-9227Gilead SciencesPhase 2/3GPRC5DCDK2i